Opinion|Videos|January 27, 2026
Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.
Advertisement
A recent real‑world analysis presented at American Society of Hematology Annual Meeting (ASH 2025) examined “time toxicity” — the burden of frequent healthcare visits and therapy‑related appointments — in patients treated with Epcoritamab. The study compared fixed‑duration regimens (such as for some bispecific antibodies) to continuous, treat‑to‑progression approaches, such as CAR-T therapies.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
Primary Care Capacity Gaps Threaten Respiratory Prevention
3
COPERNICOS Trial: Eosinophil-Guided ICS Reduction Safe in COPD, Vestbo Says
4
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
5